Developer site: The content shown here is test data.

MyEClinic
MyEClinic
Health Dictionary AI Health Chat Find an Online Doctor
A serene Zen garden with raked sand and smooth stones, symbolising clarity and calm

Health Dictionary

Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.

Back to skin conditions

TGFB1

Introduction


Transforming growth factor, beta 1, also known as TGFB1, is a human gene.

TGFB is a multifunctional peptide that controls proliferation, differentiation, and other functions in many cell types. TGFB acts synergistically with TGFA (MIM 190170) in inducing transformation. It also acts as a negative autocrine growth factor. Dysregulation of TGFB activation and signaling may result in apoptosis. Many cells synthesize TGFB and almost all of them have specific receptors for this peptide. TGFB1, TGFB2 (MIM 190220), and TGFB3 (MIM 190230) all function through the same receptor signaling systems.[supplied by OMIM][1]

References

References

  1. ↑ “Entrez Gene: TGFB1 transforming growth factor, beta 1”.
Further reading

Further reading

  • Border WA, Noble NA (1994). “Transforming growth factor beta in tissue fibrosis”. N. Engl. J. Med. 331 (19): 1286–92. PMID 7935686.
  • Munger JS, Harpel JG, Gleizes PE; et al. (1997). “Latent transforming growth factor-beta: structural features and mechanisms of activation”. Kidney Int. 51 (5): 1376–82. PMID 9150447.
  • Iozzo RV (1999). “The biology of the small leucine-rich proteoglycans. Functional network of interactive proteins”. J. Biol. Chem. 274 (27): 18843–6. PMID 10383378.
  • Reinhold D, Wrenger S, Kähne T, Ansorge S (1999). “HIV-1 Tat: immunosuppression via TGF-beta1 induction”. Immunol. Today. 20 (8): 384–5. PMID 10431160.
  • Yamada Y (2002). “Association of polymorphisms of the transforming growth factor-beta1 gene with genetic susceptibility to osteoporosis”. Pharmacogenetics. 11 (9): 765–71. PMID 11740340.
  • Chen W, Wahl SM (2002). “TGF-beta: receptors, signaling pathways and autoimmunity”. Curr. Dir. Autoimmun. 5: 62–91. PMID 11826761.
  • Marone M, Bonanno G, Rutella S; et al. (2003). “Survival and cell cycle control in early hematopoiesis: role of bcl-2, and the cyclin dependent kinase inhibitors P27 and P21”. Leuk. Lymphoma. 43 (1): 51–7. PMID 11908736.
  • Schnaper HW, Hayashida T, Hubchak SC, Poncelet AC (2003). “TGF-beta signal transduction and mesangial cell fibrogenesis”. Am. J. Physiol. Renal Physiol. 284 (2): F243–52. doi:10.1152/ajprenal.00300.2002. PMID 12529270.
  • Kalluri R, Neilson EG (2004). “Epithelial-mesenchymal transition and its implications for fibrosis”. J. Clin. Invest. 112 (12): 1776–84. doi:10.1172/JCI200320530. PMID 14679171.
  • Grainger DJ (2005). “Transforming growth factor beta and atherosclerosis: so far, so good for the protective cytokine hypothesis”. Arterioscler. Thromb. Vasc. Biol. 24 (3): 399–404. doi:10.1161/01.ATV.0000114567.76772.33. PMID 14699019.
  • Attisano L, Labbé E (2004). “TGFbeta and Wnt pathway cross-talk”. Cancer Metastasis Rev. 23 (1–2): 53–61. PMID 15000149.
  • McGowan TA, Zhu Y, Sharma K (2005). “Transforming growth factor-beta: a clinical target for the treatment of diabetic nephropathy”. Curr. Diab. Rep. 4 (6): 447–54. PMID 15539010.
  • Sheppard D (2006). “Integrin-mediated activation of latent transforming growth factor beta”. Cancer Metastasis Rev. 24 (3): 395–402. doi:10.1007/s10555-005-5131-6. PMID 16258727.
  • Gressner AM, Weiskirchen R (2006). “Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-beta as major players and therapeutic targets”. J. Cell. Mol. Med. 10 (1): 76–99. PMID 16563223.
  • Seoane J (2006). “Escaping from the TGFbeta anti-proliferative control”. Carcinogenesis. 27 (11): 2148–56. doi:10.1093/carcin/bgl068. PMID 16698802.
  • Lee CG, Kang HR, Homer RJ; et al. (2006). “Transgenic modeling of transforming growth factor-beta(1): role of apoptosis in fibrosis and alveolar remodeling”. Proceedings of the American Thoracic Society. 3 (5): 418–23. doi:10.1513/pats.200602-017AW. PMID 16799085.
  • Wahl SM (2007). “Transforming growth factor-beta: innately bipolar”. Curr. Opin. Immunol. 19 (1): 55–62. doi:10.1016/j.coi.2006.11.008. PMID 17137775.
  • Redondo S, Santos-Gallego CG, Tejerina T (2007). “TGF-beta1: a novel target for cardiovascular pharmacology”. Cytokine Growth Factor Rev. 18 (3–4): 279–86. doi:10.1016/j.cytogfr.2007.04.005. PMID 17485238.

Template:WikiDoc Sources